Imprimis Pharmaceuticals Inc. (IMMY)

2.25
0.12 5.06
NASDAQ : Health Technology
Prev Close 2.37
Open 2.35
Day Low/High 2.22 / 2.38
52 Wk Low/High 1.35 / 4.13
Volume 95.44K
Avg Volume 105.70K
Exchange NASDAQ
Shares Outstanding 20.88M
Market Cap 49.90M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Imprimis Pharmaceuticals Announces Program For Custom Compounded Ophthalmic Formulations

Imprimis Pharmaceuticals Announces Program For Custom Compounded Ophthalmic Formulations

Company dedicated to meeting the need for critical, hard-to-find medications with ease of access

Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs On FDA's Drug Shortage List

Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs On FDA's Drug Shortage List

Imprimis is dispensing preservative-free compounded dorzolamide and dorzolamide/timolol nationwide

Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility

Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility

Current Growth Expected to Continue in 2018 for the Leading Ophthalmic-Focused Compounding Business in the US

EpiPen Price Relief Could Come From Rivals Before Politicians

EpiPen Price Relief Could Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians

Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.

These 5 Under-$10 Stocks Are Set to Soar Higher

These 5 Under-$10 Stocks Are Set to Soar Higher

These under-$10 stocks look poised to break out and trade higher from current levels.

These 7 Stocks Under $10 Are Set to Soar Higher

These 7 Stocks Under $10 Are Set to Soar Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

Biotech Sector Performance February 2014: Red Hot But...

Biotech Sector Performance February 2014: Red Hot But...

An epic month of biotech stock performance ends with a significant sell off.

Imprimis Pharmaceuticals Innovates Back to Basics With Compounding

Imprimis Pharmaceuticals Innovates Back to Basics With Compounding

Few firms are positioned to take advantage of a custom Rx trend, but Imprimis has a helpful partner.

Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Faruqi & Faruqi, LLP Launches An Investigation Against Imprimis Pharmaceuticals, Inc. (IMMY) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Imprimis Pharmaceuticals, Inc.

Ratings Changes To Be Publicly Issued on 5/31/13

Upgrades: ALJ, APWC, EXH, GTN.A, HCOM, LIWA, MOBI, OSTK, SWFT, TMS, VOC Downgrades: ACU, ADK, AXR, BRP, BXE, CAP, CITZ, CLMS, CRWN, CTIB, CVTI, DAVE, DYNT, EDGW, EMMS, ESTE, HTCO, IRIX, LMIA, LNBB, MASC, MCBI, MHH, MOC, NBBC, NOVB, NWPX, PMBC, PNRG, PZZI, RBCAA, RCKY, STRN, SYNL, TOWR, TWIN, UBCP, UMPQ, USAP, WLFC Initiations: AQ, IMMY Read on to get TheStreet Quant Ratings' detailed report:

2 Biotech Stocks Under $10 to Watch

2 Biotech Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

TheStreet Quant Rating: D- (Sell)